Early real-world results of cenegermin show improved corneal sensation
Patients with neurotrophic keratitis who underwent treatment with Oxervate in a real-world setting experienced favorable improvements in corneal sensation, visual acuity and stability of the corneal epithelium, according to a speaker at the virtual American Society of Cataract and Refractive Surgery meeting.
“There may also be a particular benefit in those patients with a preexisting persistent epithelial defect or who are BCL-dependent,” Amar P. Shah, MD, MBA, said.
Shah and colleagues conducted a retrospective chart review of 57 eyes of 53 patients treated with Oxervate (cenegermin, Dompé). The primary endpoint of the study was objective improvement in corneal sensation after an 8-week course of treatment. The rate of healing of epithelial defects, the recurrence of epithelial defects, improvement in visual acuity, reduction in bandage contact lens (BCL) use and reduction in tarsorrhaphy use were evaluated during a 24-week follow-up period.
At final follow-up, 27 of 35 eyes experienced an objective increase in corneal sensation. Of 19 eyes in the study with an epithelial defect, 15 experienced complete reduction of the defect and four experienced a reduction of the defect at the 8-week conclusion of treatment.
Visual acuity improved or remained stable in 89% of eyes compared with 11% who experienced decreased vision. Of 24 eyes with a BCL at the start of treatment, 10 achieved BCL independence.
“This was one of the more interesting findings of our study, as the concurrent use of a BCL is an off-label use of cenegermin,” he said.
Zero of 16 patients with tarsorrhaphy had it removed at the conclusion of treatment, he said. – by Robert Linnehan
Shah AP. Early real-world results of topical cenegermin for the treatment of neurotrophic keratitis. Presented at: American Society of Cataract and Refractive Surgery meeting; May 16-17, 2020 (virtual meeting).
Disclosure: Shah reports no relevant financial disclosures.